Versartis nails a $55M Series E; BioMarin snags FDA nod for rare disease drug;

@FierceBiotech: Bayer moves forward in the Factor VIII hemophilia race, but Biogen is still in the lead, analyst says. More | Follow @FierceBiotech

@JohnCFierce: Looks like Actavis wants to buy Forest for $25B - not sure I really get the synergy. Story | Follow @JohnCFierce

@DamianFierce: After snow put the FDA on hold for much of last week, Chelsea Therapeutics expects Northera decision today. Release | Follow @DamianFierce

@EmilyMFierce: Role of adaptor protein could point the way for new diabetes, cancer treatments. More from FierceBiotechResearch. | Follow @EmilyMFierce

> California's Versartis has closed a $55 million E round to fund the development of VRS-317, a Phase III-ready treatment for pediatric growth hormone deficiency, bringing the company's total capital raised to $132 million. More

> BioMarin ($BMRN) won FDA approval for Vimizim, designed to treat a rare enzyme disorder called Morquio A syndrome. News

> Prana Biotechnology's ($PRAN) shares leapt more than 25% on news that its neurodegeneration drug met safety and tolerability endpoints in a midstage trial on patients with Huntington's disease, but analysts caution that the treatment failed to meet most of its secondary efficacy endpoints. Release | Commentary

Medical Device News

@FierceMedDev: For device companies, clearance for expanded use of key products = more revenue. Story | Follow @FierceMedDev

@MarkHFierce: Singapore's Biosensors International could find itself with a new owner--a Chinese equity firm. Key to a rebound? More | Follow @MarkHFierce

@MichaelGFierce: New gold nanoshells could offer better delivery of cancer drugs using near-infrared light. Release | Follow @MichaelGFierce

@EmilyWFierce: Word on the street is that Apple is developing iWatch technology to detect heart attacks. Article | Follow @EmilyWFierce

> Boston Scientific will expand the use of a key esophageal stent in Europe. More

> Welsh government refuses to cover costs associated with faulty PIP breast implants. Item

> French molecular Dx and drug outfit pulls in nearly $56.4M to fuel expansion. Story

Pharma News

@FiercePharma: Germany may publicize its drug discounts, putting fear into Big Pharma's heart. Story | Follow @FiercePharma

@TracyStaton: Call them the KOLs of biopharma: Our report on the industry's most influential people. Report | Follow @TracyStaton

@EricPFierce: FDA Commish Hamburg hopeful about cooperation from Indian regulators but some were less enthused. News | Follow @EricPFierce

@CarlyHFierce: Best-read special report over Presidents' Day weekend: Top 10 generics makers by 2012 revenue. More | Follow @CarlyHFierce

> Actavis inks $25B deal for Forest in bid to build its brand stable. Piece

> Indian regulator says his agency will not expect domestic drugmakers to hit FDA standards. Item

CRO News

> Quintiles notches its first-ever $1B quarter as sales boom. Earnings

> Parexel's rebranding makes a perceptible shift in its eClinical biz. Story

> Charles River's turnaround pays off with a strong 2013. Story

> Theorem takes a dive into analytics with latest deal. News

> After a 'pivotal' year, AMRI expects another leap in 2014. Article

> Chiltern inks a deal with Karolinska Development. Item

Biotech IT News

> Illumina takes a leaf out of the tech playbook with its genomics startup accelerator. Story

> Twitter explains how Boehringer is winning on social media. Article

> MIT proposes using robotic arms to enable smaller, cheaper stroke trials. Story

> Data science consortium outlines a vision for the future of genomic Big Data. News

> CamNtech gets an FDA nod as wearable devices advance into clinical trials. Article

> China cracks down on 'false' bird flu rumors on social media. Brief

Biotech Research News

> Role of adaptor protein could point the way for new diabetes, cancer treatments. Story

> Stem cell switch in neural cells could help treat neurological disorders. Article

> GlaxoSmithKline joins a $115M antibiotics development initiative. News

> MedImmune, UCSF strike translational research deal. News

> BioLineRx shows effectiveness of leukemia drug in preclinical study. Article

> Compound protects mice from Parkinson's-like motor loss. Item

Pharma Manufacturing News

> Mylan recalls injectable drugs after pieces of label found in some vials. News

> FDA's Hamburg comes back from India with high hopes about quality standards. Article

> Shire gets FDA nod for a second U.S. plant to make Vpriv. Story

> Ben Venue Labs may be closed but it is still recalling products. News

> Hikma's remediation costs have been offset by doxycycline sales. Story

> Amgen responds to FDA warning letter over drug/device combos. Brief

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.